Online analysis based on AAIC22 mentions in the period 19 July – 7 Aug 2022
31 Jul – 4 Aug 2022
The Alzheimer’s Association International Conference® (AAIC®) 2022 is the premier annual forum for presentation and discussion of the latest Alzheimer’s and dementia research. This year’s hybrid conference event took place both virtually and in-person in San Diego and attracted over 9,500 attendees and more than 4,000 scientific presentations.
New research reported at the AAIC 2022 covered the breadth of Alzheimer’s and dementia research, including the basic biology of aging and the brain, risk factors and prevention strategies, and caregiving and living well with the disease.
Activity Over Time:
MEDICATIONS & TREATMENTS
“Biomarkers” includes all announcements of related research and studies, such as synaptic proteins, neurofilament light chain, etc.
For the purposes of this analysis, we measured mentions of Roche and their NeuroToolKit in a separate topic. It has a 2% and 1% share of categorized mentions on LinkedIn and Twitter, respectively.
“Ongoing care” includes all conversations about novel or established methods that help diagnosed patients maintain a good quality of life.
Relative shares are calculated out of all categorised posts within the respective social media.
Competitive Brand Buzz:
Influencers & Online Buzz Strategies:
What did the highest-ranking companies in Brand Buzz analysis talk about? Click on the three dots below to flip between tabs.
TOP 10 Influencers by Conversation Impact:
Phyllis (Barkman) Ferrell
Global Head, External Engagement, Alzheimer’s and Neurodegeneration at Eli Lilly and Company
Yakeel T. Quiroz, PhD
Associate Professor of Psychiatry and Neurology at Massachusetts General Hospital
Executive Director, Stark Neurosciences Research Institute at Indiana University School of Medicine
Wiesje van der Flier
Scientific director at Alzheimer Center Amsterdam, Neuropsychologist, Clinical epidemiologist, PI Amsterdam Dementia Cohort, PI ABOARD-project
Giulio Maria Pasinetti, MD, PhD
Saunders Family Chair and Professor of Neurology at the Icahn School of Medicine at Mount Sinai
Benedict C. Albensi, PhD, BCMAS, CRQM
Chair & Professor, Pharmaceutical Sciences. Co-director B.R.A.I.N., Clinical Trials PI, Neuroscientist, Alzheimer’s Disease, Editor-in-Chief of Molecular Neurobiology
Brittany Cassin, MBA
My Every Day is Committed to Brain Health | Emerging Technology Commercialization Leader
Heleen M. A. Hendriksen
PhD student | Neuropsychologist bij Amsterdam UMC – Alzheimercentrum Amsterdam